Journal
DRUG DISCOVERY TODAY
Volume 17, Issue 7-8, Pages 367-378Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2011.10.028
Keywords
-
Categories
Funding
- European Commission [PITN-GA-2010-264506 NanoTOES]
Ask authors/readers for more resources
Injectable nanosized carriers (5-250 nm) are actively studied as anticancer drug delivery agents for targeted drug delivery to the brain. Among these, polymeric nanoparticles (Np) have been studied since 1995, but only five of them recently started Phase I clinical trials, and none of these targets brain pathologies. To date, clinical trials for brain drug delivery have started for macromolecular- and nanocarrier-based systems in the treatment of brain tumors. This review, on the basis of the results obtained so far from preclinical studies, will critically consider the possibilities that polymeric Np have to reach the clinic as drug delivery agents for the brain, in comparison with other platforms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available